| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10274), 605, 2021 | 322 | 2021 |
| Randomized controlled trial of rituximab and cost‐effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome SJ Bowman, CC Everett, JL O'Dwyer, P Emery, C Pitzalis, WF Ng, ... Arthritis & Rheumatology 69 (7), 1440-1450, 2017 | 280 | 2017 |
| A double blind placebo controlled trial of azatioprine in the treatment of primary Sjogren's syndrome EJ Price J. Rheumatol. 25, 896-899, 1998 | 160 | 1998 |
| The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome EJ Price, S Rauz, AR Tappuni, N Sutcliffe, KL Hackett, F Barone, ... Rheumatology 56 (10), e24-e48, 2017 | 138 | 2017 |
| Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a … R Lazarus, S Baos, H Cappel-Porter, A Carson-Stevens, M Clout, ... The Lancet 398 (10318), 2277-2287, 2021 | 135 | 2021 |
| Health-related utility values of patients with primary Sjögren's syndrome and its predictors D Lendrem, S Mitchell, P McMeekin, S Bowman, E Price, CT Pease, ... Annals of the rheumatic diseases 73 (7), 1362-1368, 2014 | 127 | 2014 |
| The etiopathogenesis of Sjögren's syndrome EJ Price, PJW Venables Seminars in arthritis and rheumatism 25 (2), 117-133, 1995 | 126 | 1995 |
| Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised … JR Tarn, N Howard-Tripp, DW Lendrem, X Mariette, A Saraux, ... The Lancet Rheumatology 1 (2), e85-e94, 2019 | 116 | 2019 |
| Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy BA Fisher, CC Everett, J Rout, JL O’Dwyer, P Emery, C Pitzalis, WF Ng, ... Annals of the rheumatic diseases 77 (3), 412-416, 2018 | 114 | 2018 |
| Drug-induced lupus EJ Price, PJW Venables Drug safety 12 (4), 283-290, 1995 | 106 | 1995 |
| Sjögren's Systemic Clinical Activity Index (SCAI)—a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome SJ Bowman, N Sutcliffe, DA Isenberg, F Goldblatt, M Adler, E Price, ... Rheumatology 46 (12), 1845-1851, 2007 | 104 | 2007 |
| Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome registry results M Juarez, TE Toms, P De Pablo, S Mitchell, S Bowman, P Nightingale, ... Arthritis care & research 66 (5), 757-764, 2014 | 97 | 2014 |
| Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines NH Tripp, J Tarn, A Natasari, C Gillespie, S Mitchell, KL Hackett, ... RMD open 2 (2), e000282, 2016 | 93 | 2016 |
| Phenotypic and genetic analysis of diarrhea-associated Escherichia coli isolated from children in the United Kingdom S Knutton, R Shaw, AD Phillips, HR Smith, GA Willshaw, P Watson, ... Journal of pediatric gastroenterology and nutrition 33 (1), 32-40, 2001 | 85 | 2001 |
| Dry eyes and mouth syndrome—a subgroup of patients presenting with sicca symptoms EJ Price, PJW Venables Rheumatology 41 (4), 416-422, 2002 | 79 | 2002 |
| The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren’s Syndrome S Brown, N Navarro Coy, C Pitzalis, P Emery, S Pavitt, J Gray, C Hulme, ... BMC musculoskeletal disorders 15, 1-10, 2014 | 74 | 2014 |
| The Sjögren's Syndrome Damage Index—a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome RJ Barry, N Sutcliffe, DA Isenberg, E Price, F Goldblatt, M Adler, ... Rheumatology 47 (8), 1193-1198, 2008 | 73 | 2008 |
| Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjögren's syndrome JL Newton, J Frith, D Powell, K Hackett, K Wilton, S Bowman, E Price, ... Annals of the rheumatic diseases 71 (12), 1973-1979, 2012 | 70 | 2012 |
| Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study … A Abhishek, RJ Boyton, N Peckham, Á McKnight, LC Coates, J Bluett, ... The Lancet Respiratory Medicine 10 (9), 840-850, 2022 | 68 | 2022 |
| Estimating indirect costs in primary Sjögren’s syndrome SJ Bowman, YS Pierre, N Sutcliffe, DA Isenberg, F Goldblatt, E Price, ... The Journal of rheumatology 37 (5), 1010-1015, 2010 | 67 | 2010 |
